Articles related to COGNITIVE HEALTH/MEMORY

Gantenerumab treatment generated a slowing of clinical decline from baseline score on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), but at levels that did not reach statistical significance. The relative reduction in clinical decline was 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.

At the time of this study, in 2016, dementia was seen in 10% of those over age 65 in the US, and mild cognitive impairment (MCI) in 20%, with increased risk for every 5 year advance in age. Risk was 80% higher for non-Hispanic Black individuals and approximately 40% higher in Hispanic persons, compared with White individuals. Dementia and MCI were inversely correlated with years of education, though.

A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

This study enrolled individuals with AD who had been on a stable dose of donezepil forat least 90 days. They were then treated for 12 weeks with the addition of themodulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101had mean improvement of approximately 2 points on the Alzheimer DiseaseAssessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plusplacebo showed declines on ADAS-Cog.